XORTX Advances Gout Drug Manufacturing for FDA Approval Push — XORTX Therapeutics Inc.

Event summary

XORTX initiates GMP drug substance and commercial-scale tablet manufacturing for XORLO™, its proprietary oxypurinol formulation for gout treatment.
Production supports the planned two-part XRX-OXY-102 clinical study and future FDA marketing approval.
Contract manufacturing of pure oxypurinol drug substance has begun using XORTX’s proprietary synthetic pathway.
Validation and stability data from commercial drug batches will be key for FDA NDA filing.

The big picture

XORTX’s manufacturing progress is a critical step in its strategy to bring XORLO™ to market as an alternative to existing gout treatments with safety concerns. The global prevalence of gout is rising, and XORTX aims to capitalize on this unmet need with a differentiated therapeutic option. Success hinges on navigating FDA approvals and demonstrating superior efficacy and safety in clinical trials.

What we're watching

Regulatory Strategy: The pace at which XORTX secures FDA validation and stability data for XORLO™ will determine the timeline for NDA filing.
Manufacturing Execution: Whether XORTX’s contract manufacturing partner can deliver on schedule without delays or cost overruns.
Market Differentiation: How XORLO™ positions against existing xanthine oxidase inhibitors, particularly given febuxostat’s cardiovascular risk warning.